Two people leave the same clinic a year after metabolic surgery, each twenty-nine per cent lighter, and the number written in both charts is identical. What that number is made of can differ sharply — a cohort published on 14 November in Obesity Surgery was built to show how sharply.
The study followed 276 adults in Taipei — 230 sleeve gastrectomies, 46 gastric bypasses — by bioelectrical impedance before surgery and at three, six, nine and twelve months. Total weight loss at one year was 28.9 ± 7.0 per cent. Beneath it, the authors sorted the response into three domains: tissue lost, composition reached, and the balance between fat and fat-free mass. Relative fat-mass loss climbed from 26.8 per cent at three months to 49.0 per cent at twelve; fat-free mass loss happened almost entirely early, drifting from 10.2 to 11.4 per cent, then flattening.
Two numbers moving at different speeds
Body mass index fell from 40.5 to 28.7 kg/m² — the kind of threshold movement our BMI calculator is meant to make legible. Decomposed, it is a fat mass index drop of 9.3 points against a fat-free mass index drop of 2.5, with the fat-free-to-fat ratio rising from 1.15 to 2.17. The scale registered one event; the body performed two, on different schedules.
Sex widened the gap. Total weight loss did not differ between men and women (p = 0.358), yet men lost a greater proportion of their fat mass, lost less fat-free mass, and finished the year with a higher fat-free mass index and a lower fat mass index. The sharpest caution follows: the share lost as fat-free mass did not differ by sex either (p = 0.289), and did not reflect the lean reserve a patient ended up with. Eleven participants, 4.0 per cent, finished below the threshold for low fat-free mass index. A ratio and a reserve are not the same measurement.
The design is retrospective, single-centre, impedance-based, in an East Asian population, without an untreated comparator — associations inside one clinic’s follow-up.
A meta-analysis that declines to compare
One day earlier, the same journal set surgery and incretin therapy side by side in a systematic review: 30 pooled studies, 5,616 participants, random-effects models stratified by measurement method, twelve months the primary timepoint.
The finding is directional and hedged in the same sentence. Surgery was associated with greater total weight loss and greater absolute fat-mass loss than GLP-1-based therapy in both strata. Greater absolute lean-mass loss accompanied that larger weight reduction, “without establishing poorer proportional lean-mass preservation.” Relative fat-mass change differed by modality, and heterogeneity was substantial. Then comes the sentence that governs how the result should be read: these indirect subgroup comparisons should not be interpreted as head-to-head treatment effects. What the field needs, the authors add, is standardised comparative work including muscle strength and physical function. Several authors disclose industry ties, among them a proctorship for Intuitive Surgical.
One null result, one modest one
Two intervention studies show how hard the question is to move. A triple-blind randomised trial in the Journal of Cachexia, Sarcopenia and Muscle gave 58 patients 2,000 mg of EPA plus DHA daily, or sunflower oil, for 90 days spanning surgery; skeletal muscle mass fell in both arms, 3.1 and 2.2 kg (both p < 0.001), with no interaction (p = 0.300), and grip strength and timed-up-and-go were unchanged.
Structured exercise does something, measured in kilograms and in function rather than silhouette. A meta-analysis of 33 studies and 1,545 mostly female participants in Obesity Surgery found combined training preserved fat-free mass (1.87 kg, 95% CI 0.91 to 2.83), resistance training improved strength (SMD 0.74, 0.03 to 1.45), and six-minute walk, sit-to-stand and peak oxygen uptake all improved. The recommendation is supervised combined exercise started early and sustained for six months.
The counter-argument, stated fairly
Not everyone reads lean-mass loss as injury. A perspective in Advances in Therapy argues that one-quarter to one-third of weight lost is lean mass — comparable to other effective weight-loss interventions, and consistent with remodelling rather than pathology — and that incretin therapy preferentially reduces fat, improving the lean-to-fat ratio. Its exceptions are older adults, pre-existing sarcopenia or frailty, chronic kidney or cardiovascular disease and poor nutrition, where the authors recommend measuring strength and performance rather than mass alone. The lead author discloses honoraria and advisory roles with Novo Nordisk, Eli Lilly and AstraZeneca, and an editorial board seat at the publishing journal. It is an argument at the lowest level of the evidence hierarchy, and it is the one the measurement problem has to answer.
NIDDK’s side-effects page remains the plainest statement of the stake: the body may not absorb enough nutrients after surgery, and anemia and osteoporosis can follow. Body composition is where that warning becomes visible — and where the instrument decides much of the answer, as it does when a stable weight is used to time the next reconstructive operation. A commentary in Langenbeck’s Archives of Surgery noted that fat mass, muscle mass and phase angle may follow non-parallel trajectories, so remodelling is not recovery. The LABS cohort, funded by NIDDK, follows patients prospectively with adjudicated measurements but was not built around muscle strength, which is why nobody can say what a kilogram of fat-free mass lost at three months means at ten years.
niddklabs.org is an independent archive and observatory. It is not affiliated with, endorsed by, or speaking for the NIH or NIDDK, and nothing here is medical advice.
Sources
- Distinct Body Composition Responses Despite Similar Total Weight Loss After Metabolic and Bariatric Surgery: A Retrospective Cohort Study (Obesity Surgery, published online 14 November 2026)
- Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis (Obesity Surgery, published online 13 November 2026)
- Weight-loss and body-composition trajectories after bariatric surgery may follow different timelines (Langenbeck's Archives of Surgery, 7 October 2026)
- Effects of Omega-3 Supplementation in Sarcopenia After Bariatric Surgery: A Triple-Blind Randomized Controlled Clinical Trial (Journal of Cachexia, Sarcopenia and Muscle, 2026;17(3):e70321)
- Enhancing Sarcopenia-Related Outcomes After Bariatric Surgery: A Systematic Review and Meta-Analysis of Exercise Interventions (Obesity Surgery, June 2026)
- Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern (Advances in Therapy, published online 28 September 2026)
- NIDDK — Bariatric Surgery: Side Effects
- NIDDK — Longitudinal Assessment of Bariatric Surgery (LABS)